Oz Azam (Tmunity)
Months after Tmunity ground to a halt on clinical hold, cell therapy pioneer Oz Azam is jumping to a stealth startup
Eight months after execs at Tmunity told us in an exclusive report that the FDA had slapped a clinical hold on their pipeline programs after an unexpected reaction to their cell therapies killed 2 patients and forced them to suspend their clinical trials, CEO Usman “Oz” Azam is headed out to take the helm of a stealth biotech.
Most of what we know now is limited to what Azam put in his farewell post on LinkedIn, heralding the cell therapy field as still “in the beginning”:
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters